Pharmacokinetic and Pharmacodynamic Study of Emixustat in Subjects With Geographic Atrophy Associated With Dry Age-Related Macular Degeneration

Inclusion Criteria: * Males or females age ≥65 years * Clinical diagnosis of GA associated with AMD * Able and willing to provide written informed consent * Able to reliably administer oral medication by self or with available assistance Exclusion Criteria: * Geographic atrophy associated with a condition other than AMD * History of, active or high risk of developing choroidal neovascularization (CNV) in either eye * Known serious allergy to the fluorescein sodium for injection in angiography * Pre-specified laboratory abnormalities at screening * Treatment with any investigational study drug within 30 days of screening or device within 60 days of screening * Prior participation in any clinical study of emixustat * History of other disease, metabolic dysfunction, chronic immunosuppression, physical examination finding * Male subjects who are not surgically sterile and are not willing to practice a medically accepted method of birth control with their female partner of childbearing potential from screening through 21 days after the last dose of study drug